antiGPIIBIIIa
antiGPIIBIIIa Brand names, antiGPIIBIIIa Analogs
antiGPIIBIIIa Brand Names Mixture
- No information avaliable
antiGPIIBIIIa Chemical_Formula
C6462H9964N1690O2049S48
antiGPIIBIIIa RX_link
http://www.rxlist.com/cgi/generic2/abcixim.htm
antiGPIIBIIIa fda sheet
antiGPIIBIIIa msds (material safety sheet)
antiGPIIBIIIa Synthesis Reference
(sequence listed in Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.Arterioscler Thromb. 1993 Dec;13(12):1837-42.) patent EP418316
antiGPIIBIIIa Molecular Weight
145651.1
antiGPIIBIIIa Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
antiGPIIBIIIa H2O Solubility
No information avaliable
antiGPIIBIIIa State
Liquid
antiGPIIBIIIa LogP
-0.424
antiGPIIBIIIa Dosage Forms
Solution (IV Infusion)
antiGPIIBIIIa Indication
For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina
antiGPIIBIIIa Pharmacology
Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.
antiGPIIBIIIa Absorption
No information avaliable
antiGPIIBIIIa side effects and Toxicity
No information avaliable
antiGPIIBIIIa Patient Information
No information avaliable
antiGPIIBIIIa Organisms Affected
Humans and other mammals
